BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with ...

Study subject Remains in Complete Response for 3 YearsExceeds Expectations in Platinum-Resistant Ovarian Cancer Compared to Standard of Care Single-Agent ChemotherapyVancouver, British ...